Covered recipient · General Payments record
ZIAD H YOUNES
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$61,065.07
77 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $49,105.00 | 18 |
| Travel and Lodging | $5,625.62 | 8 |
| Honoraria | $2,710.00 | 4 |
| Food and Beverage | $1,879.20 | 44 |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,000.00 | 1 |
| Consulting Fee | $656.25 | 1 |
| Education | $89.00 | 1 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Scientific Affairs, LLC | $30,202.81 | 19 |
| E.R. Squibb & Sons, L.L.C. | $13,636.85 | 9 |
| Takeda Pharmaceuticals U.S.A., Inc. | $9,078.66 | 10 |
| Intercept Pharmaceuticals, Inc. | $3,798.92 | 12 |
| AbbVie Inc. | $3,251.46 | 11 |
| Janssen Biotech, Inc. | $768.43 | 4 |
| Eisai Inc. | $115.84 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $94.46 | 4 |
| PFIZER INC. | $29.23 | 2 |
| Amgen Inc. | $20.56 | 1 |
| Ironwood Pharmaceuticals, Inc | $20.55 | 1 |
| GENZYME CORPORATION | $17.98 | 1 |
| Gilead Sciences, Inc. | $16.24 | 1 |
| SANOFI-AVENTIS U.S. LLC | $13.08 | 1 |
Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
ZIAD H YOUNES
NPI 1285619874 · CMS profile ID 194746
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
GERMANTOWN, TN
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1285619874?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- ZIAD H YOUNES, NPI 1285619874, CMS profile ID 194746. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1285619874?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). ZIAD H YOUNES, NPI 1285619874, CMS profile ID 194746. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1285619874?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- ZIAD H YOUNES, NPI 1285619874, CMS profile ID 194746, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–77 of 77 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1285619874?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
77 matching records · $61,065.07 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–77 of 77.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| AbbVie Inc. | $103.95 | 07/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796292043 | CMS |
| PFIZER INC. | $14.74 | 07/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 832667290 | CMS |
| Amgen Inc. | $20.56 | 07/21/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 825886181 | CMS |
| Ironwood Pharmaceuticals, Inc | $20.55 | 07/19/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 855128235 | CMS |
| AbbVie Inc. | $12.74 | 07/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796292041 | CMS |
| E.R. Squibb & Sons, L.L.C. | $81.35 | 07/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783437101 | CMS |
| AbbVie Inc. | $2.39 | 07/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796292039 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $19.31 | 07/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820347935 | CMS |
| AbbVie Inc. | $19.82 | 07/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796292037 | CMS |
| Janssen Scientific Affairs, LLC | $900.00 | 07/02/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788072685 | CMS |
| AbbVie Inc. | $101.00 | 06/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796292035 | CMS |
| Janssen Biotech, Inc. | $656.25 | 06/28/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788072677 | CMS |
| E.R. Squibb & Sons, L.L.C. | $99.61 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783437089 | CMS |
| AbbVie Inc. | $2.90 | 06/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796292033 | CMS |
| Janssen Biotech, Inc. | $89.00 | 06/02/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 788072679 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $48.65 | 05/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 850115151 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,015.00 | 05/11/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820347931 | CMS |
| Intercept Pharmaceuticals, Inc. | $10.30 | 05/10/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836217201 | CMS |
| AbbVie Inc. | $1,950.00 | 05/05/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796292031 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $870.00 | 05/05/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820347927 | CMS |
| Eisai Inc. | $115.84 | 05/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833754849 | CMS |
| AbbVie Inc. | $25.69 | 04/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796292029 | CMS |
| Intercept Pharmaceuticals, Inc. | $1,000.00 | 03/24/2021 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836217197 | CMS |
| Intercept Pharmaceuticals, Inc. | $8.25 | 03/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836217193 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,450.00 | 03/02/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 820347923 | CMS |
| AbbVie Inc. | $975.00 | 02/22/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 796292027 | CMS |
| Intercept Pharmaceuticals, Inc. | $750.00 | 01/20/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836217191 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $64.26 | 1 |
| PY2025 | Principal investigator | $3,862,579.53 | 370 |
| PY2024 | Principal investigator | $3,328,915.16 | 426 |
| PY2023 | Principal investigator | $3,063,905.12 | 250 |
| PY2022 | Recipient | $3,135.55 | 2 |
| PY2022 | Principal investigator | $585,955.74 | 90 |
| PY2021 | Recipient | $80,681.30 | 14 |
| PY2021 | Principal investigator | $466,408.79 | 179 |
| PY2020 | Recipient | $17,608.43 | 6 |
| PY2020 | Principal investigator | $1,189,628.39 | 408 |
| PY2019 | Recipient | $4,385.93 | 4 |
| PY2019 | Principal investigator | $2,047,867.28 | 399 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
371 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | F. Hoffmann-La Roche AG | $750.00 | 12/19/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608422 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $31,186.00 | 12/19/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608434 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $23,113.00 | 12/19/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608438 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $413.73 | 12/19/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545745 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,662.59 | 12/19/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248254264 |
| Principal investigator 1 | Eli Lilly and Company | $915.38 | 12/17/2025 | Non-covered Recipient Entity SFCT A MEMBER OF THE ALLIANCE INC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES | No dispute reported | 06/30/2026 | 1187889418 |
| Principal investigator 1 | Eli Lilly and Company | $934.02 | 12/17/2025 | Non-covered Recipient Entity SFCT A MEMBER OF THE ALLIANCE INC | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES | No dispute reported | 06/30/2026 | 1187889984 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,563.00 | 12/16/2025 | Non-covered Recipient Entity GASTRO ONE | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206825 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $39,108.00 | 12/11/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608418 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $413.73 | 12/11/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545743 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $8,977.50 | 12/10/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248253686 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $28,674.00 | 12/09/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253618 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $5,670.00 | 12/09/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248253622 |
| Principal investigator 1 | Eli Lilly and Company | $324.14 | 12/08/2025 | Non-covered Recipient Entity NORTHWEST CLINICAL RESEARCH CENTER | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1187887338 |
| Principal investigator 1 | ABBVIE INC. | $27,119.33 | 12/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) | No dispute reported | 06/30/2026 | 1202529414 |
| Principal investigator 1 | ABBVIE INC. | $8,472.50 | 12/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) | No dispute reported | 06/30/2026 | 1202529416 |
| Principal investigator 1 | ABBVIE INC. | $38,950.89 | 12/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) | No dispute reported | 06/30/2026 | 1202529418 |
| Principal investigator 1 | ABBVIE INC. | $396.36 | 12/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) | No dispute reported | 06/30/2026 | 1202529420 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $23,118.00 | 12/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608426 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,000.00 | 12/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608431 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $12,003.00 | 12/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608442 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $4,875.79 | 12/04/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545741 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $650.00 | 12/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253320 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $36,078.75 | 12/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253324 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $8,775.00 | 12/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253328 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $100.00 | 12/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253331 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,007.11 | 12/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248253335 |
| Principal investigator 1 | Genentech, Inc. | $34,726.00 | 11/25/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608731 |
| Principal investigator 1 | Genentech, Inc. | $28,325.00 | 11/25/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608735 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $413.73 | 11/25/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545739 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,021.33 | 11/25/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252829 |
| Principal investigator 1 | Genentech, Inc. | $1,605.00 | 11/20/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608742 |
| Principal investigator 1 | Gilead Sciences, Inc. | $2,617.20 | 11/19/2025 | Non-covered Recipient Entity GASTRO ONE | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209580 |
| Principal investigator 1 | Gilead Sciences, Inc. | $8,192.00 | 11/18/2025 | Non-covered Recipient Entity GASTRO ONE | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206818 |
| Principal investigator 1 | Genentech, Inc. | $288.00 | 11/14/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608707 |
| Principal investigator 1 | Genentech, Inc. | $12,013.00 | 11/14/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608717 |
| Principal investigator 1 | Genentech, Inc. | $414.00 | 11/14/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608722 |
| Principal investigator 1 | Genentech, Inc. | $813.00 | 11/14/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608739 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,404.10 | 11/14/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545737 |
| Principal investigator 1 | Gilead Sciences, Inc. | $135.00 | 11/12/2025 | Non-covered Recipient Entity GASTRO ONE | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209563 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,500.00 | 11/12/2025 | Non-covered Recipient Entity GASTRO ONE | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209573 |
| Principal investigator 1 | Gilead Sciences, Inc. | $540.00 | 11/12/2025 | Non-covered Recipient Entity GASTRO ONE | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209590 |
| Principal investigator 1 | Gilead Sciences, Inc. | $500.00 | 11/12/2025 | Non-covered Recipient Entity GASTRO ONE | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209594 |
| Principal investigator 1 | Gilead Sciences, Inc. | $183.60 | 11/12/2025 | Non-covered Recipient Entity GASTRO ONE | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209601 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,620.00 | 11/12/2025 | Non-covered Recipient Entity GASTRO ONE | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209609 |
| Principal investigator 1 | Genentech, Inc. | $8,304.00 | 11/07/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608713 |
| Principal investigator 1 | Genentech, Inc. | $12,926.00 | 11/07/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608727 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $300.00 | 11/07/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252384 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $11,603.25 | 11/07/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252388 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,662.59 | 11/07/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252392 |
| Principal investigator 1 | ABBVIE INC. | $863.08 | 11/06/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) | No dispute reported | 06/30/2026 | 1202523545 |
| Principal investigator 1 | ABBVIE INC. | $266.50 | 11/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC DBA GASTRO ONE | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202521473 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $49,013.00 | 10/29/2025 | Non-covered Recipient Entity GI Center Of The Mid Sout | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice | No dispute reported | 06/30/2026 | 1235997103 |
| Principal investigator 1 | Genentech, Inc. | $23,697.00 | 10/29/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608693 |
| Principal investigator 1 | Gilead Sciences, Inc. | $5,614.83 | 10/29/2025 | Non-covered Recipient Entity GASTRO ONE | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204755 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $5,703.25 | 10/29/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545735 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,334.85 | 10/29/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248252153 |
| Principal investigator 1 | Eli Lilly and Company | $76.65 | 10/27/2025 | Non-covered Recipient Entity SFCT A MEMBER OF THE ALLIANCE INC | A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE | No dispute reported | 06/30/2026 | 1187890186 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,457.85 | 10/27/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271429 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,727.00 | 10/27/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271436 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,800.00 | 10/27/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271463 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,457.85 | 10/27/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271471 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,457.85 | 10/27/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271504 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 10/27/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271526 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,800.00 | 10/27/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271587 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,609.40 | 10/27/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271604 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,457.85 | 10/27/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271635 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,609.40 | 10/27/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271644 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 10/27/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271655 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,727.00 | 10/27/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271728 |
| Principal investigator 1 | Genentech, Inc. | $32,130.00 | 10/23/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608696 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $827.46 | 10/23/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545733 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,929.50 | 10/23/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251775 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $50.00 | 10/23/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251779 |
| Principal investigator 1 | Genentech, Inc. | $17,261.00 | 10/16/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608681 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $3,733.41 | 10/16/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545729 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,571.30 | 10/16/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545731 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $8,669.70 | 10/16/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248251500 |
| Principal investigator 1 | ABBVIE INC. | $7,385.00 | 10/10/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC DBA GASTRO ONE | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202516545 |
| Principal investigator 1 | ABBVIE INC. | $2,288.25 | 10/10/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202516559 |
| Principal investigator 1 | Genentech, Inc. | $6,188.00 | 10/09/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608684 |
| Principal investigator 1 | Genentech, Inc. | $37,345.00 | 10/09/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608704 |
| Principal investigator 1 | Genentech, Inc. | $38,408.00 | 10/03/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608688 |
| Principal investigator 1 | Genentech, Inc. | $19,554.00 | 10/03/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608700 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $3,225.25 | 10/03/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545719 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $500.00 | 10/03/2025 | Non-covered Recipient Entity Gastro One | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176545721 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,200.00 | 10/03/2025 | Non-covered Recipient Entity Gastro One | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176545723 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,000.00 | 10/03/2025 | Non-covered Recipient Entity Gastro One | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176545725 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $600.00 | 10/03/2025 | Non-covered Recipient Entity Gastro One | A Phase II, Multicenter, Double-Blind, Randomised, Placebo-Controlled Study and Open Label Long Term Extension to Evaluate the Safety and Efficacy of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis (PSC). | No dispute reported | 06/30/2026 | 1176545727 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $11,638.70 | 10/03/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250956 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $7,624.10 | 10/03/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248250960 |
| Recipient | Eli Lilly and Company | $64.26 | 10/02/2025 | Covered Recipient Physician | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF LY4268989 (MORF-057) CO-ADMINISTERED WITH MIRIKIZUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS | No dispute reported | 06/30/2026 | 1187872715 |
| Principal investigator 1 | ABBVIE INC. | $10,161.45 | 09/26/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202512530 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $12,439.00 | 09/23/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608273 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,334.85 | 09/23/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250538 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $9,777.00 | 09/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608260 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,242.00 | 09/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608294 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,448.00 | 09/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608301 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $56,878.00 | 09/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608321 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $9,777.00 | 09/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608325 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $468.00 | 09/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608337 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $29,331.00 | 09/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608345 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $88.00 | 09/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608358 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $767.00 | 09/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608367 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $234.00 | 09/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608371 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,066.00 | 09/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608378 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $351.00 | 09/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608383 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $117.00 | 09/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608399 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,000.00 | 09/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608405 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $4,875.79 | 09/18/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545713 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,662.59 | 09/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250169 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,223.00 | 09/16/2025 | Non-covered Recipient Entity GASTRO ONE | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206810 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $37,040.00 | 09/12/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608297 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,556.11 | 09/12/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545711 |
| Principal investigator 1 | ABBVIE INC. | $2,255.85 | 09/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202510192 |
| Principal investigator 1 | ABBVIE INC. | $17,850.00 | 09/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab (REVAMP) | No dispute reported | 06/30/2026 | 1202510194 |
| Principal investigator 1 | Gilead Sciences, Inc. | $4,483.80 | 09/05/2025 | Non-covered Recipient Entity GASTRO ONE | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209556 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $8,002.00 | 09/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608254 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $468.00 | 09/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608317 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $144.00 | 09/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608362 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $828.00 | 09/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608375 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $19,554.00 | 09/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608387 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $144.00 | 09/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608413 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $4,597.92 | 09/04/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545709 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $23,209.88 | 09/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249464 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $500.00 | 09/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249469 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,327.74 | 09/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248249471 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $66.00 | 09/01/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545715 |
| Principal investigator 1 | Genentech, Inc. | $763.00 | 08/27/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211608673 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,116.00 | 08/26/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608246 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $36,620.00 | 08/26/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608277 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $117.00 | 08/26/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608306 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $1,380.00 | 08/26/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608355 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $994.50 | 08/26/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545705 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,083.72 | 08/22/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248248987 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $234.00 | 08/21/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608290 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,655.48 | 08/21/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248842 |
| Principal investigator 1 | Gilead Sciences, Inc. | $54,652.00 | 08/19/2025 | Non-covered Recipient Entity GASTRO ONE | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206802 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $28,214.00 | 08/14/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608333 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $345.80 | 08/14/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545717 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,334.85 | 08/14/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248380 |
| Principal investigator 1 | ABBVIE INC. | $3,375.00 | 08/08/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202504103 |
| Principal investigator 1 | ABBVIE INC. | $20,322.90 | 08/08/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202504107 |
| Principal investigator 1 | ABBVIE INC. | $2,760.75 | 08/08/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202504109 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $10,479.00 | 08/07/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608251 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $29,331.00 | 08/07/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608329 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $413.73 | 08/07/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545701 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $981.35 | 08/07/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545703 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,334.85 | 08/07/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248096 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 08/06/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271511 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 08/06/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271627 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,000.00 | 08/06/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271704 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 08/01/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545707 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $4,001.00 | 07/31/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608264 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $48,625.00 | 07/31/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608281 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $414.00 | 07/31/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608285 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $28,980.00 | 07/31/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608303 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,511.00 | 07/31/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608313 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $2,898.00 | 07/31/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608341 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $12,009.00 | 07/31/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608395 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $351.00 | 07/31/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608409 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,511.65 | 07/31/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545691 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,327.74 | 07/31/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248247698 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,581.25 | 07/30/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247595 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,609.40 | 07/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271671 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,457.85 | 07/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271680 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,457.85 | 07/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271697 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,457.85 | 07/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271713 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,457.85 | 07/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271739 |
| Principal investigator 1 | Genentech, Inc. | $1,526.00 | 07/25/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211608677 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $980.00 | 07/25/2025 | Non-covered Recipient Entity GASTRO ONE | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171164 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $39,748.00 | 07/22/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608269 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $8,002.00 | 07/22/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608391 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $4,616.64 | 07/22/2025 | Non-covered Recipient Entity GASTRO ONE | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171166 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $5,574.79 | 07/22/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545687 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,340.00 | 07/22/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545689 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,809.00 | 07/22/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247369 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,007.11 | 07/22/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248247373 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,511.65 | 07/17/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545685 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,014.22 | 07/17/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248247123 |
| Principal investigator 1 | Gilead Sciences, Inc. | $10,588.50 | 07/16/2025 | Non-covered Recipient Entity GASTRO ONE | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204747 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $675.00 | 07/11/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247030 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $675.00 | 07/11/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247034 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,404.00 | 07/11/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248247038 |
| Principal investigator 1 | F. Hoffmann-La Roche AG | $16,243.00 | 07/10/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608351 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $216.00 | 07/10/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545677 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $135.00 | 07/10/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545679 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $675.00 | 07/10/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545681 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,823.00 | 07/10/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545693 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $405.00 | 07/10/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545695 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $223.00 | 07/10/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545697 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $223.00 | 07/10/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545699 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,662.59 | 07/10/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246778 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $16,420.62 | 07/10/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248246782 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $300.00 | 07/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246420 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $22,244.63 | 07/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246424 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,768.50 | 07/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246428 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,014.22 | 07/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246433 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $18,049.51 | 07/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246437 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $13,685.26 | 07/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246441 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $400.00 | 07/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246445 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,768.50 | 07/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246449 |
| Principal investigator 1 | ABBVIE INC. | $2,463.75 | 07/03/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202496823 |
| Principal investigator 1 | ABBVIE INC. | $530.40 | 07/03/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC DBA GASTRO ONE | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202496825 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $35,775.00 | 07/02/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248246290 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 07/01/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545683 |
| Principal investigator 1 | Genentech, Inc. | $234.00 | 06/24/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608491 |
| Principal investigator 1 | Genentech, Inc. | $1,242.00 | 06/24/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608495 |
| Principal investigator 1 | Genentech, Inc. | $3,999.00 | 06/24/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608533 |
| Principal investigator 1 | Genentech, Inc. | $38,874.00 | 06/24/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608553 |
| Principal investigator 1 | Genentech, Inc. | $138.00 | 06/24/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608562 |
| Principal investigator 1 | Genentech, Inc. | $117.00 | 06/24/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608583 |
| Principal investigator 1 | Genentech, Inc. | $279.00 | 06/24/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608642 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $3,728.47 | 06/24/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545673 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,514.40 | 06/24/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246211 |
| Principal investigator 1 | Genentech, Inc. | $1,104.00 | 06/19/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608529 |
| Principal investigator 1 | Genentech, Inc. | $9,777.00 | 06/19/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608545 |
| Principal investigator 1 | Genentech, Inc. | $27,965.00 | 06/19/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608594 |
| Principal investigator 1 | Genentech, Inc. | $20,343.00 | 06/19/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608631 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,097.92 | 06/19/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545671 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,014.22 | 06/19/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245945 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $7,500.17 | 06/12/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545661 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,404.10 | 06/12/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545663 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $669.50 | 06/12/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545665 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,072.50 | 06/12/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545667 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $104.00 | 06/12/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545669 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,334.85 | 06/12/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245569 |
| Principal investigator 1 | Eli Lilly and Company | $1,095.09 | 06/11/2025 | Non-covered Recipient Entity SFCT A MEMBER OF THE ALLIANCE INC | A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE CROHNS DISEASE AND OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187889064 |
| Principal investigator 1 | Genentech, Inc. | $763.00 | 06/11/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211608669 |
| Principal investigator 1 | Eli Lilly and Company | $1,014.78 | 06/10/2025 | Non-covered Recipient Entity SFCT A MEMBER OF THE ALLIANCE INC | A PHASE 3B, RANDOMIZED, MULTICENTER, CONTROLLED STUDY OF MIRIKIZUMAB AND PLACEBO OR MIRIKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS AND OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187890184 |
| Principal investigator 1 | Genentech, Inc. | $10,000.00 | 06/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608513 |
| Principal investigator 1 | Genentech, Inc. | $117.00 | 06/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608558 |
| Principal investigator 1 | Genentech, Inc. | $837.00 | 06/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608569 |
| Principal investigator 1 | Genentech, Inc. | $1,104.00 | 06/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608578 |
| Principal investigator 1 | Genentech, Inc. | $28,980.00 | 06/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608587 |
| Principal investigator 1 | Genentech, Inc. | $690.00 | 06/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608590 |
| Principal investigator 1 | Genentech, Inc. | $351.00 | 06/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608597 |
| Principal investigator 1 | Genentech, Inc. | $9,777.00 | 06/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608610 |
| Principal investigator 1 | Genentech, Inc. | $19,320.00 | 06/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608623 |
| Principal investigator 1 | Genentech, Inc. | $351.00 | 06/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608629 |
| Principal investigator 1 | Genentech, Inc. | $2,200.00 | 06/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608636 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $11,080.13 | 06/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245093 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $200.00 | 06/05/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245098 |
| Principal investigator 1 | ABBVIE INC. | $5,303.20 | 06/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC DBA GASTRO ONE | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202490075 |
| Principal investigator 1 | ABBVIE INC. | $2,255.85 | 06/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202490077 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 06/01/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545675 |
| Principal investigator 1 | ABBVIE INC. | $4,742.40 | 05/29/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH | Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) | No dispute reported | 06/30/2026 | 1202486835 |
| Principal investigator 1 | ABBVIE INC. | $66,495.00 | 05/29/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH | Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) | No dispute reported | 06/30/2026 | 1202486837 |
| Principal investigator 1 | ABBVIE INC. | $11,302.20 | 05/29/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH | Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) | No dispute reported | 06/30/2026 | 1202486843 |
| Principal investigator 1 | ABBVIE INC. | $1,430.00 | 05/29/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH | Study Comparing Intravenous (IV) Subcutaneous (SC) Risankizumab to IV SC Ustekinumab to Assess Change in Crohn Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn Disease (CD) | No dispute reported | 06/30/2026 | 1202486845 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $981.35 | 05/28/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545657 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,014.22 | 05/28/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244740 |
| Principal investigator 1 | Genentech, Inc. | $14,883.00 | 05/27/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608574 |
| Principal investigator 1 | Genentech, Inc. | $14,155.00 | 05/27/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608614 |
| Principal investigator 1 | Genentech, Inc. | $763.00 | 05/23/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211608654 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,564.65 | 05/22/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545655 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,014.22 | 05/22/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244381 |
| Principal investigator 1 | Genentech, Inc. | $10,951.00 | 05/15/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608606 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $22,353.98 | 05/15/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248243957 |
| Principal investigator 1 | ABBVIE INC. | $9,055.80 | 05/08/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202484277 |
| Principal investigator 1 | Genentech, Inc. | $7,108.00 | 05/08/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608506 |
| Principal investigator 1 | Genentech, Inc. | $3,204.00 | 05/08/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608538 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $5,988.52 | 05/08/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545653 |
| Principal investigator 1 | ABBVIE INC. | $3,853.90 | 05/07/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC DBA GASTRO ONE | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202482655 |
| Principal investigator 1 | ABBVIE INC. | $2,193.68 | 05/07/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202482657 |
| Principal investigator 1 | Genentech, Inc. | $202,195.00 | 05/07/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211608651 |
| Principal investigator 1 | Gilead Sciences, Inc. | $1,030.77 | 05/07/2025 | Non-covered Recipient Entity GASTRO ONE | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204741 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 05/01/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545659 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $3,944.10 | 04/30/2025 | Non-covered Recipient Entity TENNESSEE COMPREHENSIVE LUNG AND SLEEP CENTER | A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele | No dispute reported | 06/30/2026 | 1185546101 |
| Principal investigator 1 | Genentech, Inc. | $3,999.00 | 04/28/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608518 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $6,672.71 | 04/28/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545649 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $4,726.25 | 04/28/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545651 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,175.00 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271405 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271412 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,875.35 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271419 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,457.85 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271443 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,457.85 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271458 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271478 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271487 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,800.00 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271495 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271534 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,457.85 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271544 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,800.00 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271552 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,875.35 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271560 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,800.00 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271565 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,800.00 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271575 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,609.40 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271582 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,609.40 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271596 |
| Principal investigator 1 | Janssen Research & Development, LLC | $348.00 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271612 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,800.00 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271620 |
| Principal investigator 1 | Janssen Research & Development, LLC | $348.00 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271648 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,800.00 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271663 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,457.85 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271689 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,457.85 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271721 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,609.40 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271746 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,800.00 | 04/28/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271753 |
| Principal investigator 1 | Genentech, Inc. | $319,206.00 | 04/25/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211608660 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $5,980.00 | 04/23/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545637 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $955.00 | 04/23/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545639 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $72.80 | 04/23/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545643 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $8,580.00 | 04/23/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545645 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $780.00 | 04/23/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545647 |
| Principal investigator 1 | ABBVIE INC. | $5,879.25 | 04/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202478067 |
| Principal investigator 1 | ABBVIE INC. | $627.75 | 04/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202478072 |
| Principal investigator 1 | ABBVIE INC. | $41,850.00 | 04/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202478075 |
| Principal investigator 1 | ABBVIE INC. | $7,807.05 | 04/18/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202478079 |
| Principal investigator 1 | Genentech, Inc. | $10,658.00 | 04/15/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608523 |
| Principal investigator 1 | Genentech, Inc. | $2,514.00 | 04/15/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608527 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $5,224.70 | 04/15/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545635 |
| Principal investigator 1 | Genentech, Inc. | $152,600.00 | 04/09/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211608665 |
| Principal investigator 1 | Genentech, Inc. | $3,969.00 | 04/08/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608627 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,880.91 | 04/08/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545633 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $18,442.36 | 04/08/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248241902 |
| Principal investigator 1 | ABBVIE INC. | $3,343.84 | 04/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202474395 |
| Principal investigator 1 | ABBVIE INC. | $10,312.65 | 04/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202474399 |
| Principal investigator 1 | Genentech, Inc. | $7,454.00 | 04/03/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) | No dispute reported | 06/30/2026 | 1211608542 |
| Principal investigator 1 | Genentech, Inc. | $9,777.00 | 04/03/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608601 |
| Principal investigator 1 | Genentech, Inc. | $9,777.00 | 04/01/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608565 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $5,161.06 | 04/01/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545631 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 04/01/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545641 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $4,620.00 | 03/27/2025 | Non-covered Recipient Entity GASTRO ONE | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171162 |
| Principal investigator 1 | Genentech, Inc. | $2,222.00 | 03/25/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608460 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,925.38 | 03/25/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545627 |
| Principal investigator 1 | Genentech, Inc. | $7,804.00 | 03/19/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608479 |
| Principal investigator 1 | Gilead Sciences, Inc. | $19,915.20 | 03/19/2025 | Non-covered Recipient Entity GASTRO ONE | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | No dispute reported | 06/30/2026 | 1229209548 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,511.65 | 03/19/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545623 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,571.30 | 03/19/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545625 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $446.00 | 03/14/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545619 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,349.00 | 03/14/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545621 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $8,354.72 | 03/11/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545615 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $6,000.00 | 03/11/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545617 |
| Principal investigator 1 | ABBVIE INC. | $3,299.40 | 03/10/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202462216 |
| Principal investigator 1 | Genentech, Inc. | $763.00 | 03/07/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211608450 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $28,870.38 | 03/06/2025 | Non-covered Recipient Entity GASTRO ONE | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248240354 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $48,039.26 | 03/06/2025 | Non-covered Recipient Entity GASTRO ONE | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248240360 |
| Principal investigator 1 | Genentech, Inc. | $66,533.00 | 03/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608455 |
| Principal investigator 1 | Genentech, Inc. | $39,108.00 | 03/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608464 |
| Principal investigator 1 | Genentech, Inc. | $3,174.00 | 03/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608469 |
| Principal investigator 1 | Genentech, Inc. | $1,100.00 | 03/04/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608472 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $32,977.00 | 03/04/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545613 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 03/01/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545629 |
| Principal investigator 1 | Genentech, Inc. | $2,200.00 | 02/25/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608499 |
| Principal investigator 1 | Genentech, Inc. | $14,726.00 | 02/25/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608619 |
| Principal investigator 1 | Genentech, Inc. | $10,000.00 | 02/25/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608639 |
| Principal investigator 1 | Genentech, Inc. | $9,660.00 | 02/25/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211608646 |
| Principal investigator 1 | Intercept Pharmaceuticals, Inc. | $4,616.64 | 02/20/2025 | Non-covered Recipient Entity GASTRO ONE | A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis | No dispute reported | 06/30/2026 | 1248171160 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $7,074.00 | 02/13/2025 | Non-covered Recipient Entity GASTRO ONE | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248239718 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $9,286.00 | 02/12/2025 | Non-covered Recipient Entity Gastro One | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice | No dispute reported | 06/30/2026 | 1235997225 |
| Principal investigator 1 | ABBVIE INC. | $4,719.60 | 02/07/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202450227 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8.50 | 02/07/2025 | Non-covered Recipient Entity Gastro One | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271519 |
| Principal investigator 1 | ABBVIE INC. | $1,502.04 | 02/06/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202447874 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $44,983.70 | 02/06/2025 | Non-covered Recipient Entity GASTRO ONE | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248239163 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $6,075.00 | 02/06/2025 | Non-covered Recipient Entity GASTRO ONE | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248239168 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $52,289.90 | 02/06/2025 | Non-covered Recipient Entity GASTRO ONE | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248239172 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $981.35 | 02/05/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545609 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 02/01/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545611 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $103,170.25 | 01/31/2025 | Non-covered Recipient Entity GASTRO ONE | A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele | No dispute reported | 06/30/2026 | 1185546099 |
| Principal investigator 1 | Gilead Sciences, Inc. | $8,707.14 | 01/29/2025 | Non-covered Recipient Entity GASTRO ONE | An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) | No dispute reported | 06/30/2026 | 1229204733 |
| Principal investigator 1 | Eli Lilly and Company | $110,867.00 | 01/28/2025 | Non-covered Recipient Entity SFCT A MEMBER OF THE ALLIANCE INC | A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE | No dispute reported | 06/30/2026 | 1187889402 |
| Principal investigator 1 | Eli Lilly and Company | $877.05 | 01/27/2025 | Covered Recipient Teaching Hospital UNIVERSITY OF WASHINGTON MED CTR | A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE | No dispute reported | 06/30/2026 | 1187871309 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,457.85 | 01/27/2025 | Non-covered Recipient Entity Gastroenterology Ctr Of The Midsouth | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175271451 |
| Principal investigator 1 | Eli Lilly and Company | $7.65 | 01/15/2025 | Non-covered Recipient Entity SFCT A MEMBER OF THE ALLIANCE INC | A MULTICENTER, PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB | No dispute reported | 06/30/2026 | 1187889404 |
| Principal investigator 1 | Genentech, Inc. | $61,803.00 | 01/13/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC | Roche Cancer Screening Collection Study | No dispute reported | 06/30/2026 | 1211608445 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $38,734.60 | 01/13/2025 | Non-covered Recipient Entity GASTRO ONE | A PHASE 3B OPEN-LABEL STUDY TO DETERMINE THE LONG-TERM SAFETY AND EFFICACY OF VEDOLIZUMAB SUBCUTANEOUS IN SUBJECTS WITH ULCERATIVE COLITIS AND CROHN'S DISEASE | No dispute reported | 06/30/2026 | 1223273893 |
| Principal investigator 1 | Eli Lilly and Company | $74,946.60 | 01/10/2025 | Non-covered Recipient Entity SFCT A MEMBER OF THE ALLIANCE INC | A MULTICENTER, PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB | No dispute reported | 06/30/2026 | 1187891696 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $981.35 | 01/07/2025 | Non-covered Recipient Entity Gastro One | A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid. (ELSPIRE) | No dispute reported | 06/30/2026 | 1176545607 |
| Principal investigator 1 | ABBVIE INC. | $122.88 | 01/03/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | No dispute reported | 06/30/2026 | 1202436401 |
| Principal investigator 1 | ABBVIE INC. | $1,928.10 | 01/03/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH PLLC DBA GASTRO ONE | M16-066 - A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis | No dispute reported | 06/30/2026 | 1202436405 |
| Principal investigator 1 | ABBVIE INC. | $4,511.70 | 01/03/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF | M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease | No dispute reported | 06/30/2026 | 1202436408 |
| Principal investigator 1 | ABBVIE INC. | $1,130.00 | 01/03/2025 | Non-covered Recipient Entity GASTROENTEROLOGY CENTER OF THE MIDSOUTH | M16-000 - A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202436464 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $90.00 | 01/01/2025 | Non-covered Recipient Entity Gastro One | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545605 |